Mood Disorders  >>  Phase 2
Welcome,         Profile    Billing    Logout  

681 Trials

   Remove Filter

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Mood Disorders
ATTUNE, NCT04951076: A Phase 2b Study of BNC210 Tablet Formulation in Adults With Post-Traumatic Stress Disorder (PTSD)

Completed
2b
212
Europe, US
BNC210, Placebo
Bionomics Limited
Post-Traumatic Stress Disorder
07/23
08/23
ACTRN12624001021561: Do cannabidiol and diazepam interact? A proof-of-concept clinical trial.

Not yet recruiting
2
15
 
The University of Sydney, Lambert Initiative for Cannabinoid Therapeutics
Anxiety
 
 
ACTRN12624000871549: Pilot investigation of psychedelic-assisted psychotherapy for treatment of post-traumatic stress disorder (PTSD) in people diagnosed with co-occurring borderline personality disorder – a controlled before-and-after study

Not yet recruiting
2
20
 
Spectrum Personality Disorder Service for Victoria, Spectrum Personality Disorder Service for Victoria
borderline personality disorder (BPD), post-traumatic stress disorder (PTSD)
 
 
ACTRN12616001001482p: Cannabidiol (CBD) for Cannabis and Mood Disorders in Adolescence (CCAMDA)

Not yet recruiting
2
20
 
University of New South Wales, National Cannabis Prevention and Information Centre
Mood disorders; Cannabis use
 
 
ACTRN12618001393246p: Ketamine in anorexia nervosa

Not yet recruiting
2
24
 
University of Otago, University of Otago
anorexia nervosa; depressive disorder; anxiety disorder; obessional disorder
 
 
ACTRN12619001334190p: The Effect of 3, 4-Methylenedioxymethamphetamine (MDMA)-assisted therapy on Mood and Anxiety symptoms in advanced-stage Cancer Study

Not yet recruiting
2
24
 
University of Otago, University of Otago
Depression symptoms; Anxiety symptoms; Advanced-stage cancer
 
 
ACTRN12618001393246: Ketamine in anorexia nervosa

Not yet recruiting
2
24
 
University of Otago, University of Otago
anorexia nervosa, depressive disorder, anxiety disorder, obessional disorder
 
 
ACTRN12609001013257: Methylphenidate for Borderline Personality Disorder in Adolescents

Not yet recruiting
2
30
 
Concord Hospital, Department of Psychiatry, Concord Hospital, Department of Psychiatry
Borderline Personality Disorder (BPD)
 
 
ACTRN12624000816550: Feasibility study testing the protocol of single dose of psilocybin given to people who have had little improvements with brief psychological intervention

Not yet recruiting
2
30
 
University of Otago, University of Otago, Ashburn Clinic: James Humes Bequest Fund
Anxiety, Depression
 
 
ACTRN12607000478415: Optimal timing for femoral fracture fixation in multiple trauma patients

Not yet recruiting
2
40
 
The Alfred, Transport Accident Commission
Multi-system trauma with femoral shaft fracture
 
 
ACTRN12616001113448: KARVIAH Sub-study: Examining the use of curcumin on cognition and mood in an older population

Not yet recruiting
2
40
 
Macquarie University, Anglicare Community Services
Alzheimer's disease, depression
 
 
ACTRN12611000610932: Therapeutic effect of saffron on cognitive function in multiple sclerosis patients

Not yet recruiting
2
60
 
Tehran University of medical science, green plants of life
Multiple sclerosis, Cognitive dysfunction, Depression
 
 
ACTRN12609000384257: Heads Up: A Phase II trial of a radiotherapy-based intervention for depression and malnutrition in Head and Neck cancer patients.

Not yet recruiting
2
70
 
Calvary Mater Newcastle, Cancer Institute NSW
Malnutrition and depression in Head and Neck Cancer during radiotherapy
 
 
ACTRN12621001358831p: Psilocybin-assisted psychotherapy for Generalised Anxiety Disorder

Not yet recruiting
2
72
 
Monash University, Incannex Healthcare Ltd
Generalised Anxiety Disorder
 
 
ACTRN12615000522516: A study comparing resuscitation outcomes following administration of an intravenous oxygen carrier (HBOC-201) to Normal Saline in urban adult trauma patients.

Not yet recruiting
2
110
 
Alfred Health, Alfred Health, HbO2 Therapeutics LLC
Haemorrhagic shock, Major Trauma
 
 
ACTRN12623001004651: Evaluating the management of treatment resistant depression with psychedelic (psilocybin) assisted psychotherapy (EMPACT)

Not yet recruiting
2
140
 
The Australian National University, Australian Department of Health and Aged Care -Medical Research Future Fund, The Australian National University, Mynd Life Sciences
Treatment Resistant Depression
 
 
ACTRN12613001276741: Effect of supplementary oral L-tyrosin plus 5-hydroxytriptophan on severity of Parkinson's Disease; a clinical trial

Not yet recruiting
2
153
 
Daniel F Fouladi, Tabriz University of Medical Sciences, Drug Applied Research Center
Parkinson's Disease
 
 
ACTRN12622000474752p: TIDE (Trimetazidine in bipolar depression): A double-blind, randomised, placebo-controlled trial

Not yet recruiting
2
180
 
Deakin University, Stanley Medical Research Institute
Bipolar depression
 
 
ACTRN12624000236594: Treating anxiety in young people (12-25 years) using Cannabidiol (CBD) when conventional anxiety treatments have proven ineffective.

Not yet recruiting
2
180
 
Orygen Centre for Youth Mental Health, The Medical Research Future Fund (MRFF) Department of Health and Aged Care
Anxiety, Treatment-Resistant Anxiety
 
 
ACTRN12623000544673: Online Cognitive Behavioural Therapy for Death Anxiety: A Randomised Controlled Trial

Not yet recruiting
2
184
 
The University of Sydney, National Health and Medical Research Council
Death Anxiety
 
 
ACTRN12606000413527: Treatment Evaluation of Alcohol and Mood

Not yet recruiting
2
220
 
Professor Doug Sellman, Ministry of Health, University of Otago
Alcoholism, Depression
 
 
ACTRN12613001275752: Effect of supplementary oral 5-hydroxytryptophan on severity of depression in patients on chronic selective serotonin reuptake inhibitors; a clinical trial

Not yet recruiting
2
240
 
Daniel F Fouladi, Tabriz University of Medical Sciences, Drug Applied Research Center
Major depression
 
 
ACTRN12622000474752: TIDE (Trimetazidine in bipolar depression): A double-blind, randomised, placebo-controlled trial

Not yet recruiting
2
260
 
Deakin University, Stanley Medical Research Institute
Bipolar depression
 
 
ACTRN12621001222831: Impact of Pharmacogenetic Testing on Cost Effectiveness in Mental Illness

Not yet recruiting
2
1032
 
Flinders University of South Australia, Flinders University
Major depressive disorder (MDD), Schizophrenia, , schizoaffective disorder, bipolar disorder
 
 
ACTRN12613000274774: The effects of minocycline on breathing during sleep in patients prescribed opioid drugs for chronic pain.

Recruiting
2
15
 
Repatriation General Hospital, The Repat Foundation
Central sleep apnoea, chronic pain
 
 
ACTRN12617001130358: A Study of Ketamine in Elderly Patients with Depression.

Recruiting
2
24
 
University of Otago, University of Otago
Depression
 
 
ACTRN12611000810910: The effect of Tai Ji Quan on stress

Recruiting
2
30
 
University of Technology, Sydney
Anxiety
 
 
ACTRN12622000669796: Intranasal insulin for neurocognition in bipolar disorder

Recruiting
2
44
 
Swinburne University of Technology, Milken Institute
Bipolar disorder, neurocognition
 
 
ACTRN12610001011077: Rapid depression treatment in cancer patients

Recruiting
2
50
 
University of Otago, University of Otago
Major depressive disorder, Cancer
 
 
ACTRN12612000420842: Novel Treatment of Phobias in Children and Teenagers

Recruiting
2
70
 
Dr Allison Waters, Griffith University
Pediatric Specific Phobia Disorder
 
 
ACTRN12622001359729: D-Cycloserine Augmentation of Intermittent Theta Burst Stimulation (iTBS) in Depression

Recruiting
2
180
 
Alfred Health, Monash Alfred Psychiatry Research Centre
Major Depressive Disorder
 
 
ACTRN12608000042347: From rehabilitation to recovery: A model to optimise consumer and carer involvement in the first year post stroke

Active, not recruiting
2
120
 
St.Vincent's Health Melbourne, Auatralian Research Council (ARC)
Stroke, Depression, Quality of Life, Carer burden
 
 
ACTRN12614000411640: The Post Anaesthesia N-Acetycysteine Cognitive Evaluation trial, investigating the potential for N-Acetylcysteine to reduce cognitive dysfunction following major elective non-cardiac surgery

Recruiting
2
370
 
The Geelong Hospital, The Geelong Hospital, CRC for Mental Health, Sydney Parker Smith Scholarship
Post Operative Cognitive Dysfunction , Surgical Stress Response, Post Operative Mood Disorder, Post surgical pain
 
 
ACTRN12616000473460: Efficacy of D-Cycloserine in combination with intensive exposure therapy in the treatment of obsessive compulsive disorder (OCD) in children

Recruiting
2
80
 
Dr Lara Farrell, National Health and Medical Research Council
Pediatric Obsessive Compulsive Disorder
 
 
ACTRN12620001015932: Double-Blind Randomised Investigation of Bazedoxifene and Conjugated Estrogen for Depression in Menopausal Women

Recruiting
2
90
 
Monash University, Monash University
Depression, Menopause
 
 
ACTRN12621000429853: Oral Ketamine Trial on people aged 16 years and older with Treatment-Resistant Depression

Recruiting
2
25
 
Thompson Institute, University of the Sunshine Coast, Thompson Institute, University of the Sunshine Coast
Treatment-Resistant Depression
 
 
ACTRN12616001001482: Cannabiol (CBD) for Cannabis and Mood Disorders in Young Adults (CCAMDYA)

Recruiting
2
30
 
St Vincent's Hospital Melbourne, St Vincent's Hospital Melbourne
Mood disorders, Cannabis use
 
 
ACTRN12621001097831: A study of psilocybin-assisted psychotherapy for treatment-resistant depression (TRD)

Recruiting
2
15
 
Swinburne University of Technology , Swinburne University of Technology , St Vincent's Hospital Melbourne, The Barbara dicker Brain Sciences Foundation, Usona Institute
Treatment Resistant Depression (TRD)
 
 
ACTRN12617001317381: Estrogen for the treatment of Borderline Personality Disorder

Recruiting
2
72
 
Alfred Hospital, Monash Alfred Psychiatry Research Centre
Borderline Personality Disorder
 
 
ACTRN12623000838617: A study to investigate the safety and feasibility of delivering MDMA-assisted psychotherapy to patients with posttraumatic stress disorder

Recruiting
2
5
 
Emyria Ltd, Emyria Ltd
Posttraumatic Stress Disorder
 
 
ACTRN12619001334190: Effect of 3, 4-Methylenedioxymethamphetamine (MDMA)-assisted therapy on Mood and Anxiety symptoms in patients with advanced-stage Cancer Study (EMMAC Study)

Recruiting
2
32
 
University of Otago, University of Otago, Individual donor, Multidisciplinary Association for Psychedelic Studies (MAPS), Individual donor, Multidisciplinary Association for Psychedelic Studies (MAPS)
Depression symptoms, Anxiety symptoms, Advanced-stage cancer
 
 
ACTRN12623000872639: The effects of cannabidiol (CBD) on psychosocial stress, situational anxiety and nausea experienced in a virtual reality environment

Recruiting
2
74
 
University of Sydney, Lambert Initiative for Cannabinoid Therapeutics
Psychosocial stress , Situational anxiety , Motion sickness, Cybersickness
 
 
ACTRN12623000971639: MDMA-assisted therapy for Post-Traumatic Stress Disorder in Military Veterans and First Responders

Recruiting
2
24
 
Monash University, Monash University, Philanthropic - private, Multidisciplinary Association for Psychedelic Studies
Post-Traumatic Stress Disorder
 
 
ACTRN12623001080617: An Open Label Safety and Efficacy Study of XW10508 Modified Release (MR) in Patients with Major Depressive Disorder

Recruiting
2
24
 
XW Laboratories (Australia) Pty Ltd, XW Laboratories (Australia) Pty Ltd
Major Depressive Disorder
 
 
ACTRN12623000812695: Efficacy and safety of prehospital fibrinogen early in severe trauma study: A feasibility phase II study (PRE-FEISTY II) (Stage 1).

Recruiting
2
23
 
New South Wales Ambulance, NSW Ambulance
Acute traumatic haemorrhage
 
 
ACTRN12623001064695: Low dose psilocybin as a treatment for moderate depression

Recruiting
2
293
 
Macquarie University, Woke Pharmaceuticals
Major Depressive Disorder of moderate severity
 
 
ACTRN12622001525774: Developing Optimal Psychedelic Assisted Psychotherapy for Obsessive-Compulsive Disorder

Recruiting
2
40
 
Australian National University, Monarch Mental Health Group
Treatment Resistant Obsessive-Compulsive Disorder
 
 
ACTRN12624000128594: Assessing the effects of Lysergic acid diethylamide (LSD) microdosing in people experiencing depression (LSDDEP2)

Recruiting
2
90
 
The University of Auckland, Health Reseach Council of New Zealand, MindBio Therapeutics Ltd
Major Depressive Disorder (MDD)
 
 
2004-000502-40: A thematic analysis of semi-structured interviews using a phenomenological approach into palliative care patients experiences of change in "fatigue" following treatment with methylphenidate– an exploratory study

Ongoing
2
15
Europe
Methylphenidate hydrochloride, Tablet, Ritalin
Southampton University Hospitals Trust
Patients with cancer in palliative stage of their illness. Suffering from fatigue with or without decreased concentration, depression or drowsiness, who feel their fatigue is severe enough to decrease their quality of life.
 
 
2005-003409-98: Enhancement by tacrolimus of nerve regeneration after peripheral nerve repair.

Ongoing
2
10
Europe
Prograf, FK506, Capsule, hard, Prograf 0.5 mg Capsules, Prograf 1 mg Capsules, Prograf 5 mg Capsules
Hôpital Erasme, Cliniques Universitaires de Bruxelles
Patients presenting a total section of a major nerve at the arm, forearm, or leg, and treated by conventional nerve suture under microscope within ten days of the trauma. Patients with nerve autografts performed in good conditions (well-vascularized bed, absence of tension, operation performed within 4 months after the nerve section) can be included in the study.
 
 
ChiCTR-TRC-12002614: A phase II clinical research on Renzhu Jianwei granule in treating chronic atrophic gastritis (qi deficiency, blood stasis and hot depression syndrome)

Completed
2
240
 
Renzhujianwei granule ;Weifuchun tablet
General Hospital of Shenyang Military Region; General Hospital of Shenyang Miliary Region, Nanjing Zhongshan Pharmaceutical Factory
chronic atrophic gastritis
 
 
2006-005531-17: Xenon als Antidepressivum

Ongoing
2
20
Europe
Xenon pro Anaesthesia, Inhalation gas, Xenon pro Anaesthesia
Klinik für Anästhesiologie Universitätsklinikum Aachen
Major depressive disorder and recurrent mayor depressive disorder (ICD 10 F32.2 and 33.3)
 
 
2010-022673-33: The Dexametasone-CRH-test as a potential predictor of treatment effect in depression: a pilot study.

Ongoing
2
40
Europe
Citalopram Cnspharma, Tablet, citalopram
Psykiatri Nordväst, Karolinska Universitetssjukhuset Solna, AFA and the Swedish Research Council
In total 40 subjects, aged 20-65 years, with depressive symptoms, considered by their physician to need antidepressant treatment, will be recruited from primary care clinics in the Stockholm area.
 
 
GRATITUDE, ChiCTR-TRC-09000375: The Effects of Gratitude on Psychological Well-being

Completed
2
720
 
Gratitude - participants write 2 diaries per week for 1 month, focusing on thankful events ;Hassles - participants write 2 diaries per week for 1 month, focusing on hassles ;Participants will be normal adults and health-care workers. In the control group, no intervention will be given.
Department of Psychological Studies, Hong Kong Institute of Education,; None, Self-finance
Depression (depressive symptoms)
 
 
ChiCTR-TNRC-11001528: Efficacy of Umbilical cord Mesenchymal stem cells transplantation in the treatment of brain trauma sequela patients

Completed
2
40
 
rehabitation therapy ;stem cell transplantation
General Hospital of Chinese People's Armed Police Forces; General Hospital of Chinese People's Armed Police Forces, General Hospital of Chinese People's Armed Police Forces
brain trauma sequela
 
 
2012-005372-34: Can telaprevir and paroxetine be used together?

Ongoing
2
16
Europe
Film-coated tablet, Incivo, Paroxetine Sandoz
Radboud University Nijmegen Medical Centre, Janssen Cilag
chronic hepatitis C infection with depression, chronic hepatitis C infection with depression, Diseases [C] - Virus Diseases [C02]
 
 
GLND Trauma, NCT01776476: A Randomized Controlled Trial of Glutamine Dipeptide in Severe Trauma

 
2
24
US
Glutamine, Glutamine Dipeptide, Placebo, Surgery
Ziegler, Thomas R., M.D.
Stress Hyperglycemia, Insulin Resistance, Trauma, Critical Illness
07/13
02/14
2013-002545-10: An open safety study with the monoaminergic stabilizer (-)-OSU6162 in patients with mental fatigue and related vitality and wakefulness disturbances associated with neurologiacal disorders, e g Parkinson’s disease, Huntington’s disease, brain trauma, stroke, myalgic encephalomyelitis and narcolepsy. En öppen studie av säkerhet hos den monoaminerga stabiliseraren (-)-OSU6162 hos patienter med mental trötthet och därmed relaterad vitalitets- och vakenhetsstörning registrerade vid neuro-psykiatriska sjukdomar som Parkinsons sjukdom, Huntingtons sjukdom, traumatisk hjärnskada, stroke, Myalgisk encefalomyelit och narkolepsi.

Ongoing
2
240
Europe
OSU6162 similar to (-)-OSU 6162, Coated tablet
A. Carlsson Research AB, A. Carlsson Research AB
Parkinsons disease Huntingtons disease Multiple scleros Brain trauma Stroke Myalgic encephalomyelitis Narcolepsy Parkinsons sjukdom Huntingtons sjukdom Multipel scleros Traumatisk hjärnskada Stroke Myalgisk encefalomyelit Narkolepsi, Parkinsons disease Huntingtons disease Multiple scleros Brain trauma Stroke Myalgic encephalomyelitis Narcolepsy Parkinsons sjukdom Huntingtons sjukdom Multipel scleros Traumatisk hjärnskada Stroke Myalgisk encefalomyelit Narkolepsi, Diseases [C] - Nervous System Diseases [C10]
 
 
ACTRN12614000525684: FAB study: Fan, Activity and Breathlessness: assessing the fan’s capacity to increase physical activity in patients with breathlessness and reducing carer anxiety

Active, not recruiting
2
60
 
The University of Notre Dame Australia, , Sacred Heart Clinical Trials Unit, The Cunningham Centre for Palliative Care
Breathlessness, Physical activity, Self management, Self-efficacy - care givers
 
 
2013-003196-35: Assessing the subjective intensity of oral psilocybin in patients with treatment-resistant depression

Ongoing
2
12
Europe
Psilocybin, Psilocybin, Capsule
Imperial College London
Major depressive disorder, Pervasive and persistent low mood that is accompanied by low self-esteem and by a loss of interest or pleasure in normally enjoyable activities., Psychiatry and Psychology [F] - Mental Disorders [F03]
 
 
2014-004937-15: Effects of BNC210 on human brain activity in anxious subjects.

Ongoing
2
24
Europe
BNC210 300mg, BNC210 2000mg, Powder for oral suspension
BIONOMICS LIMITED, BIONOMICS LIMITED
Generalized Anxiety Disorder, Generalized Anxiety Disorder, Psychiatry and Psychology [F] - Behaviours [F01]
 
 
ChiCTR-IPR-14005341: The establishment and verification of traditional chinese medicine for depression using Combined Disease and Symdrome

Recruiting
2
120
 
traditional Chinese medicine ;zoloft
Guangdong Hospital of Chinese Medicine; Guangdong Hospital of Chinese Medicine, Science and Technology Department of Guangdong Province
Depression
 
 
2015-001456-29: A Double-blind, Placebo-controlled, Randomized, Multicenter Proof-of-principle Trial of Adjunctive Minocycline for Patients With Treatment Resistant Unipolar Major Depressive Disorder (MDD) Eine doppelt-verblindete, placebo-kontrollierte, randomisierte, mulitzentrische Studie zur Überprüfung der Wirksamkeit einer Minocyclinaugmentation bei Patienten mit therapierefraktärer unipolarer depressiver Erkrankung

Ongoing
2
160
Europe
Minocycline, Capsule, hard, Udima
Charité - Universitätsmedizin Berlin, Bundeministerium für Bildung und Forschung (BMBF)
Minocycline, a broad-spectrum and central nervous system entering tetracycline, reduces within an additional therapy the symptomatology of depressive patients. Minocyclin, ein pleiotropes, ZNS-gängiges Tetrazyklin, reduziert im Rahmen einer Begleittherapie die Symptomatik von depressiven Patienten. Ursächlich hierfür ist u.a. eine anti-inflammatorische sowie neuroprotektive Wirkung., Minocycline, a broad-spectrum and central nervous system entering tetracycline, reduces within an additional therapy the symptomatology of depressive patients. Minocyclin, ein Tetrazyklin, reduziert im Rahmen einer Begleittherapie die Symptomatik von depressiven Patienten durch u.a. seine anti-inflammatorische sowie neuroprotektive Wirkung., Psychiatry and Psychology [F] - Mental Disorders [F03]
 
 
2004-002540-94: Effects of allopregnanolone in women with PMDD, depression, PCOS och oral contraceptives

Ongoing
2
50
Europe
Allopregnanolone, UC1009,
Norrlands university hospital
PMDD (premenstrual dysphoric disorder) includes depressed mood and anxiety but occurs only during the late phase of the menstrual cycle. Major depression are more common in women and especially post partum and during the menopause. PCOS (polycystic ovary syndrome) include symptoms like hirsutism, amenorrhoea and obesity but depressive symptom also occur. Mental side effects from oral contraceptives are common.
 
 
2004-002577-23: Efficacy and safety of Agomelatine (25 mg with potential adjustment at 50 mg) given orally once a day for 12 weeks in out-patients with Generalised Anxiety Disorder. A randomised flexible dose double-blind, placebo-controlled, parallel groups, international study.

Ongoing
2
80
Europe
S20098-F55,
Institut de Recherches Internationales Servier
Generalised Anxiety Disorder
 
 
2005-003750-10`ACTRN12617000547347: Growth hormone and androgens in the treatment of glucocorticoid induced protein catabolism

Ongoing
2
12
Europe
Genotropin, Testogel, Genotropin, Testogel, Genotropin, Testogel
VästraGötaland, Movember
Depression, Anxiety
 
 
2006-001475-38: A DOUBLE BLIND, PLACEBO CONTROLLED, RANDOMIZED, SEQUENTIAL GROUP, MULTIPLE DOSE STUDY OF THE EFFICACY OF THE CRF1-RECEPTOR ANTAGONIST R317573 ON CCK-4 INDUCED ANXIETY IN HEALTHY MALE SUBJECTS.

Ongoing
2
72
Europe
R317573 200 mg, R317573 10 mg, R317573 50 mg, F006, F008, F007,
Janssen Cliag Ltd. C/O Johnson & Johnson PRD
Anxiety and depression
 
 
2006-003659-19: A Double Blind, Placebo- and Active-Controlled, Randomized, Sequential Group, Multiple Dose Study to Examine the Effect of the CRF1-Receptor Antagonist R317573 on 7.5% CO2-Inhalation Induced Anxiety in Healthy Subjects

Ongoing
2
32
Europe
R317573 10mg, R317573 50mg, N/A, F008, F007, F320, Temesta 1mg, Temesta 1mg
Janssen-Cilag International N.V.
Anxiety disorders and depression
 
 
2006-003912-23: A Phase IIa, double-blind, placebo-controlled, randomised, parallel-group study, to investigate the safety, tolerability and anxiolytic effect of the mGluR5 negative allosteric modulator ADX10059 in patients with dental anxiety undergoing dental treatment.

Ongoing
2
50
Europe
ADX10059, ADX10059,
Addex Pharmaceuticals SA
Dental anxiety
 
 
2006-003571-12: Breath Methionine and Other Indices of Oxidant Stress in the Critical Care Setting. The effect of two doses of Dipeptiven given independently of parenteral nutrition.

Ongoing
2
60
Europe
Dipeptiven, Dipeptiven
Barts and the London NHS Trust
60 consecutive critically ill patients will be recruited with illnesses such as severe infection, trauma and post-surgery.
 
 
2006-006443-30: A phase IIa open-label study using ICX-RHY to enhance the aesthetic appearance of facial skin imperfections.

Ongoing
2
10
Europe
ICX-RHY-013, ICX-RHY-013,
Intercytex
Facial skin imperfections such as small scars, depressions, pock-marks and other localised contour deformities of healthy adults
 
 
2007-000083-24: A survey of efficacy of zolpidem in patients with brain injury including SPECT brain scans in selected patients

 
2
300
Europe
Stilnoct®, Stilnoct®
Regen Therapeutics PLC
Brain damage of any original cause, such as strokes, trauma, birth injury, post-viral infection.
 
 
2008-000453-35: Open-label phase IIa pilot study exploring safety and potential efficacy of recombinant human erythropoietin in early mild Alzheimer Dementia and therapy-refractory Major Depression (“EPO-AD”)

Ongoing
2
20
Europe
Erypo, Erypo
Max-Planck-Institute of Experimental Medicine
Early, mild dementia of the Alzheimer’s Type and therapy-refractory Major Depression
 
 
2007-005564-27: Effect of agomelatine (25 mg) given orally once a day for 7 days on cerebral activity measured by functional MRI during processing of emotional stimuli in patients with Major Depressive Disorder. A randomised, double-blind, placebo-controlled study with an open extension period of 6 months with agomelatine (25 mg).Comparison to functional MRI profiles of healthy volunteers.

Ongoing
2
60
Europe
S20098, S20098,
Institut de Recherches Internationales Servier
Major Depressive Disorder
 
 
2008-007110-29: An international randomised, double-blind, placebo-controlled study to assess the efficacy and safety of 2 dosing regimens of FIBRINOGENE T1 in the treatment of peri-operative bleeding associated with revision total hip arthroplasty

Ongoing
2
60
Europe
Human fibrinogen, FGT1,
LFB BIOTECHNOLOGIES
Severe Acute Haemorrhage (SAH)The main clinical situations of SAH are trauma and surgery-related haemorrhages and obstretical haemorrheges. Othopedic procedures can induce SAH. One of the most haemorrhagic types of surgery is revision total hip arthroplasty (THA). For the purpose of the study patient with elective revision THA including major acetabular and/or femoral reconstruction.
 
 
2009-011115-20: Nordic Longterm OCD treatment Study: A Nordic Multicenter treatment study evaluating a stepped care model based on the \"Expert Clinical Guidelines\". The study is performed with no sponsor from pharmaceutical firms.

Ongoing
2
11
Europe
aripripazol, abilify, Abilify, Abilify
The Centre for Child and Adolescent Mental Health, Eastern and Southern Norway (R.BUP), The Centre for Child and Adolescent Mental Health, Eastern and Southern
Obsessive Compulsive Disorder
 
 
2008-000281-23: Melatonin in Acute Mania Investigation (MIAMI-UK)

Ongoing
2
90
Europe
Circadin, Circadin, Circadin
University of Oxford
Bipolar Disorder (mania and hypomania)
 
 
2009-014056-30: Reconnaissance des expressons faciales émotionnelles chez les patients présentant un épisode dépressif magnétique transcranienne répétée du cortex préfrontal dorsolatéral droit à basse fréquence et/ou venlafaxine

Ongoing
2
60
Europe
Effexor, Effexor
CHU Clermont-Ferrand
depression
 
 
2010-020906-14: Investigation on the efficacy of treatment of patients with functional abdominal pain and anxiety disorder with escitalopram, compared to placebo.

Ongoing
2
80
Europe
Escitalopram, NL/H/0984/001, escitalopram, escitalopram
MUMC, MUMC
IBS and panic disorder
 
 
2011-003654-40: A study to see if the medication Ketamine can relieve depression in people who have not responded to another class of medication called Selective Serotonin Re-uptake Inhibitors (SSRIs)

Ongoing
2
20
Europe
ketalar, ketalar
Department of Psychiatry, Department of Psychaitry
Depression
 
 
2015-004587-11: Is dexmedetomidine a safe medicine to calm elderly patients when they are waiting for an operation?

Ongoing
2
48
Europe
Solution for infusion, Dexdor
University Medical Center Groningen, University Medical Center Groningen
Anxiety, preoperative, Fear and anxiety in the hours directly preceding a surgical procedure, Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Anesthesia and Analgesia [E03]
 
 
2014-001541-24: Neuroenhancement of Interpersonal Psychotherapy in Major Depression Augmentation von Interpersoneller Psychotherapie durch D-Cycloserin

Ongoing
2
28
Europe
Cycloserin-Kapseln, Capsule, hard, Cycloserine
University Medical Center Freiburg, University Medical Center Freiburg
Major Depression (ICD-10; F32.2/F33.2) Depressive Störung (ICD-10; F32.2/F33.2), Disorder in which the fundamental disturbances are a change in affect or mood to depression and a usually accompanied change in the overall level of activity. Störung deren Hauptsymptome eine Veränderung der Stimmung oder der Affektivität zur Depression hin und eine Veränderung des allgemeinen Aktivitätsniveaus sind., Psychiatry and Psychology [F] - Mental Disorders [F03]
 
 
2015-000301-40: Trauma Organ Protection - Artesunate

Ongoing
2
105
Europe
Artesunate 10mg/ml, ST7570, Powder and solvent for solution for infusion
Queen Mary University of London, The Wellcome Trust Ltd
Organ Dysfunction and Failure in Traumatic Hemorrhage, Organ failure following severe injury-induced critical bleeding, Diseases [C] - Injuries, poisonings, and occupational diseases [C21]
 
 
2010-018486-37: Treatment of exacerbations of post-traumatic stress disorder by short-term dexamethasone, a pilot study.

Ongoing
2
10
Europe
Dexacortal, Dexacortal
Kris-och Traumacentrum
Posttraumatic stress syndrome F431
 
 

Ongoing
2
54
Europe
Bocouture (Botulinumtoxin A), Powder for solution for injection, Bocouture
Medizinische Hochschule Hannover, Asklepios Klinik Nord, Medizinische Hochschule Hannover
Borderline personality disorder Borderline-Persönlichkeitsstörung, n.a., Psychiatry and Psychology [F] - Mental Disorders [F03]
 
 
2015-003676-70: Preanesthetic medication in pediatric patients: A comparison of midazolam, clonidine and dexmedetomidine

Ongoing
2
300
Europe
Klonidinhydroklorid APL, Concentrate and solvent for solution for infusion, Oral solution, Dexdor, Klonidin APL, Midazolam APL
Norrbottens läns landsting, Norrbottens läns landsting, Umeå university
Is there a difference in anxiety- and sedation-level, and in anesthesia induction compliance between the preanesthetics included in study, in pediatric patients? Can we prevent and reduce anxiety without causing negative cardiorespiratory effects by selected preanesthetic included in study, in TIVA in pediatric patients? Does the preanesthetic used in this study prevent and/or reduce pain, vomiting, shivering, events of emergence delirium and maladaptive behaviors, without prolonging recovery?, This study investigates the anxiety and sedation in children before and after anesthesia, comparing the effects of three different sedative medicines given to the child to facilitate the anesthesia., Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Anesthesia and Analgesia [E03]
 
 
NCT01375114: The Effects of Ginseng on Cancer-Related Fatigue

Active, not recruiting
2
165
US
Panax Ginseng, Placebo, Sugar Pill, Questionnaires, Surveys
M.D. Anderson Cancer Center, Indena S.p.A
Advanced Cancers, Solid Tumors
05/16
10/25
2015-000465-31: An 8-week randomized, double-blind, placebo-controlled clinical trial of Cannabidiol as add-on therapy in bipolar depression Eine 8-wöchige, randomisierte, doppelblinde, placebo-kontrollierte klinische Studie mit Cannabidiol als Add-on-Therapie zur Behandlung der bipolaren Depression

Ongoing
2
126
Europe
Cannabidiol, CBD, Capsule, hard
Charité - Universitätsmedizin Berlin, Charité - Universitätsmedizin Berlin
Bipolar disorder, current episode depressed Bipolare affektive Störung, gegenwärtig depressive Episode, Bipolar disorder, current episode depressed aktuelle depressive Episode bei einer Bipolaren Störung, Psychiatry and Psychology [F] - Mental Disorders [F03]
 
 
2015-002255-10: Can artificially made human erythropoietin improve recovery after major injuries?

Ongoing
2
10
Europe
Eprex (rhEPO), NA, Solution for injection in pre-filled syringe, Eprex
Abertawe Bro Morgannwg University Health Board, Abertawe Bro Morgannwg University Health Board
Post-trauma multiple organ failure: a manifestation of the systemic inflammatory/immune response to major injuries., This study will see if artificially made human erythropoietin helps people recover from serious injury quicker by boosting immunity through bone marrow or improving the way the body creates energy., Body processes [G] - Immune system processes [G12]
 
 
2016-001715-21: Ketamine for depression

Ongoing
2
120
Europe
Infusion, Ketamine (Ketalar by Pfizer)
UZ Leuven, IWT Agentschap voor Innovatie door Wetenschap en Technologie
Major depressive disorder and Bipolar Disorder I and II, depression, Psychiatry and Psychology [F] - Mental Disorders [F03]
 
 
2015-004527-32: Sitagliptin is an established diabetes drug medication that acts primarily by stimulating the body’s ability to release insulin, leading to a lowering of blood sugar levels. This clinical trial will examine whether treatment with Sitagliptin can improve both depression and type 2 diabetes together

Ongoing
2
60
Europe
Januvia (Sitagliptin), Capsule, hard, Januvia (Sitagliptin)
King's College London, Kings College Hospital NHS Foundation Trust, KHP BRC Experimental Medicine Pilot Project Award
Depression in type 2 diabetes, Depression in type 2 diabetes, Psychiatry and Psychology [F] - Mental Disorders [F03]
 
 
ChiCTR-IPR-14005672: The therapeutic effect of statins on patients with depression after acute coronary syndrome

Recruiting
2
180
 
Rosavastatin calcium 20mg/d p.o. ;sertraline 25-50 mg/d p.o. ;Rosavastatin calcium 5mg/d p.o.
Tongji Hospital Affiliated to Tongji University; Tongji hospital affiliated to Tongji University, Shanghai Municipal Health Bureau
depression secondary to coronary artery disease
 
 
2016-002068-14: Investigation of antidepressant efficacy of oral ketamine treatment

Ongoing
2
60
Europe
Solution for injection/infusion, Ketamin-hameln, Dormicum
Medical University of Vienna, Medical University of Vienna
Major depressive episode (Major depressive disorder, Biploar disorder), Depression, Psychiatry and Psychology [F] - Mental Disorders [F03]
 
 
2015-000323-86: Ebselen as an add-on treatment in hypo/mania

Not yet recruiting
2
60
Europe
SPI-1005, Ebselen, NA, Capsule
University of Oxford, The Stanley Medical Research Institute
Patients with bipolar disorder meeting DSM-5 criteria for hypomania or mania, Bipolar disorder is characterised by periods of elevated mood and periods of depression. The elevated mood is known as hypomania or mania: an individual feels abnormally happy, energetic or irritable., Psychiatry and Psychology [F] - Mental Disorders [F03]
 
 
NCT02804022: Vital-signs-integrated Patient-assisted Intravenous Opioid Analgesia

Active, not recruiting
2
20
RoW
VPIA analgesia, VPIA delivery system, Morphine, Morphine-VPIA
KK Women's and Children's Hospital
Respiratory Depression
05/17
12/24
2017-002232-16: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TAK-653 in the Treatment of Subjects with Treatment-Resistant Depression

Not yet recruiting
2
90
Europe
TAK-653, TAK-653, Tablet
Millennium Pharmaceuticals, Inc, a wholly owned subsidiary of Takeda Pharmaceutical Company, Ltd, Millennium Pharmaceuticals, Inc, a wholly owned subsidiary of Takeda Pharmaceutical Company, Ltd
Treatment Resistant Depression, Psychiatry and Psychology [F] - Mental Disorders [F03]
 
 
2017-004624-30: The role of brain inflammation in depression

Ongoing
2
66
Europe
Solution for injection in pre-filled syringe, RoActemra
Linköping University, Region Östergötland
Major depressive disorder, Depression, Psychiatry and Psychology [F] - Mental Disorders [F03]
 
 
2018-002140-88: A study to evaluate the safety, tolerability and efficacy of ORY-2001 in aggressionin patients with Alzheimer's Disease, Lewy Body Dementia, Adult attention Deficit Hyperactivity Disorder, Borderline Personality Disorder, Autism Spectrum Disorder Estudio para evaluar la seguridad, tolerabilidad y eficacia de ORY-2001 en el tratamiento de la agresividad en pacientes con Enfermedad de Alzheimer, Demencia de Cuerpos de Lewy, Trastorno por Déficit de Atención e Hiperactividad, Trastorno Límite de la Personalidad y Trastorno del Espectro Autista.

Ongoing
2
30
Europe
ORY-2001, Capsule
Oryzon Genomics S.A., Oryzon Genomics S.A.
Agression Agresividad, Agression Agresividad, Diseases [C] - Nervous System Diseases [C10]
 
 
2018-001212-30: A trial to study effects of a single dose Citalopram on emotion processing in patients with Borderline Personality Disorder and the associated modulation of fMRI BOLD signals

Ongoing
2
30
Europe
Film-coated tablet, Citalopram
Central Institute of Mental Health, represented by commercial and administrative Director, Boehringer Ingelheim Pharma GmbH & Co KG
Borderline Personality Disorder, Borderline Personality Disorder, Psychiatry and Psychology [F] - Mental Disorders [F03]
 
 
2016-004974-16: Trial treating brain injured patients with the anti-inflammatory drug Kineret: IL1ra-TBI

Ongoing
2
60
Europe
Kineret, Injection, Kineret
Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge, Sobi (Swedish Orphan Biovitrum AB), Swedish Society of Medicie, National Institute of Health Research, Swedish Brain Foundation
We wish to study the drug Kineret in patients suffering from moderate-to-severe traumatic brain injury, Traumatic brain injury is defined as blunt trauma to the brain causing injuries and hemorrhages, which in turn lead to a harmful environment for surviving brain cells., Diseases [C] - Nervous System Diseases [C10]
 
 
 

Download Options